Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Cellectar Biosc WT (CLRBW)

Cellectar Biosc WT (CLRBW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference GlobeNewswire - Fri Jan 9, 7:05AM CST

Following Guidance from the European Medicines Agency’s (EMA) Scientific Advice Working Party (SAWP) Regarding Iopofosine I 131 for the Treatment of Waldenstrom’s Macroglobulinemia (WM), Expects to...

CLRBZ : 0.12 (-14.27%)
CLRB : 3.29 (+4.78%)
CLRBW : 0.13 (+348.28%)
Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies GlobeNewswire - Tue Dec 16, 2025

FLORHAM PARK, N.J. and LANSING, Mich., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development...

CLRBZ : 0.12 (-14.27%)
CLRB : 3.29 (+4.78%)
CLRBW : 0.13 (+348.28%)
Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire - Thu Nov 13, 2025

Expects to Submit Conditional Marketing Approval Application in Europe for Iopofosine I 131 in Refractory (post-BTKi) Waldenstrom’s Macroglobulinemia in 2026 Following Advice and Guidance from Scientific...

CLRBZ : 0.12 (-14.27%)
CLRB : 3.29 (+4.78%)
CLRBW : 0.13 (+348.28%)
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025 GlobeNewswire - Thu Nov 6, 2025

FLORHAM PARK, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for...

CLRBZ : 0.12 (-14.27%)
CLRB : 3.29 (+4.78%)
CLRBW : 0.13 (+348.28%)
Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma GlobeNewswire - Mon Oct 27, 2025

FLORHAM PARK, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for...

CLRBZ : 0.12 (-14.27%)
CLRB : 3.29 (+4.78%)
CLRBW : 0.13 (+348.28%)
Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research GlobeNewswire - Tue Oct 14, 2025

FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for...

CLRBZ : 0.12 (-14.27%)
CLRB : 3.29 (+4.78%)
CLRBW : 0.13 (+348.28%)
Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million GlobeNewswire - Tue Oct 7, 2025

FLORHAM PARK, N.J., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB) (“Cellectar” or the “company”), a late-stage biotechnology company focused on the discovery and...

CLRBZ : 0.12 (-14.27%)
CLRB : 3.29 (+4.78%)
CLRBW : 0.13 (+348.28%)
Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM) GlobeNewswire - Mon Oct 6, 2025

Following Scientific Advice and Guidance from Scientific Advice Working Party (SAWP) of EMA, Submission of CMA Application for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) WM  Expected...

CLRBZ : 0.12 (-14.27%)
CLRB : 3.29 (+4.78%)
CLRBW : 0.13 (+348.28%)
Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer GlobeNewswire - Tue Sep 30, 2025

FLORHAM PARK, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for...

CLRBZ : 0.12 (-14.27%)
CLRB : 3.29 (+4.78%)
CLRBW : 0.13 (+348.28%)
Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC) GlobeNewswire - Wed Sep 24, 2025

FLORHAM PARK, N.J. and LONDON and CHARLOTTESVILLE, Va., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (“Cellectar”) (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company...

CLRBZ : 0.12 (-14.27%)
CLRB : 3.29 (+4.78%)
CLRBW : 0.13 (+348.28%)

Barchart Exclusives

Is AMD Stock a Buy? Why Wall Street Sees 40% Upside From Here. Barchart - Sun Feb 15, 9:00AM CST
AMD is well-positioned for strong growth in 2026, driven by rising demand in the data center and PC markets. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot